Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Irinotecan
Drug: Oxaliplatin
Drug: Levoleucovorin
Drug: 5-FU
Drug: GM-CSF
Drug: IL-2

First Posted Date: 2017-07-19

Last Posted Date: 2018-03-27

Lead Sponsor: Fujian Cancer Hospital

Registration Number: NCT03222089

Locations: 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2

Active, not recruiting

Conditions: Kidney Cancer

Interventions: Drug: Pembrolizumab
Drug: Interleukin-2

First Posted Date: 2016-11-15

Last Posted Date: 2025-01-10

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT02964078

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Active, not recruiting

Conditions: High Grade Serous Ovarian Cancer
Primary Peritoneal Cancer
Recurrent
Platinum-resistant
Fallopian Tube Cancer

Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs)
Biological: Interleukin-2
Drug: Cyclophosphamide

First Posted Date: 2013-06-21

Last Posted Date: 2024-03-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 3

Registration Number: NCT01883297

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Dose D3 of interleukin-2
Drug: Dose D2 of Interleukin-2
Drug: placebo
Drug: Dose D1 of interleukin-2

First Posted Date: 2013-05-24

Last Posted Date: 2020-11-12

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 24

Registration Number: NCT01862120

Locations: 🇫🇷
CIC pédiatrique - CHU de Necker, Paris, France
🇫🇷
Service d'Endocrinologie Pédiatrique, Le Kremlin Bicetre, France
🇫🇷
Service de Pédiatrie - CHU de Nîmes, Nimes, France

and more 3 locations

Proleukin and Rapamune in Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: IL-2
Drug: Rapamycin

First Posted Date: 2007-09-06

Last Posted Date: 2017-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9

Registration Number: NCT00525889

Locations: 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States
🇺🇸
Benaroya Research Institute, Seattle, Washington, United States

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1

Completed

Conditions: Lung Cancer
Melanoma
Ovarian Sarcoma
Eye Cancer
Adult Soft Tissue Sarcoma
Colorectal Cancer
Breast Cancer
Uterine Sarcoma
Bone Cancer
Colon Cancer

First Posted Date: 2007-03-06

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020267

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Phase 2

Completed

Conditions: Extraocular Extension Melanoma
Recurrent Intraocular Melanoma

First Posted Date: 2007-03-06

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020475

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

First Posted Date: 2007-03-05

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019448

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies

Completed

Conditions: HIV Infections

Interventions: Drug: Interleukin-2

First Posted Date: 2006-04-06

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00311688

Locations: 🇺🇸
NIH Intramural Research Program ACTG CRS, Bethesda, Maryland, United States

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: IL-2

First Posted Date: 2005-05-16

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 267

Registration Number: NCT00110812

Locations: 🇺🇸
NIH Clinical Ctr., NIAID HIV Clinic CRS, Bethesda, Maryland, United States
🇺🇸
Providence Portland Med. Ctr., Ambulatory Care and Education Ctr. CRS, Portland, Oregon, United States
🇺🇸
Washington DC VAMC, Washington Regional AIDS Program, Infectious Diseases CRS, Washington, District of Columbia, United States

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy